JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock

Glaukos (NYSE:GKOS) had its price objective raised by investment analysts at JPMorgan Chase & Co. from $200.00 to $240.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price objective points to a potential downside of 0.34% from the company’s current price.

GKOS has been the topic of several other research reports. Needham & Company LLC lifted their price target on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday. Mizuho set a $225.00 price target on Glaukos in a report on Thursday. BTIG Research increased their price target on shares of Glaukos from $205.00 to $234.00 and gave the company a “buy” rating in a report on Thursday. UBS Group started coverage on Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $216.71.

Glaukos Price Performance

Glaukos stock traded up $59.38 during mid-day trading on Thursday, hitting $240.81. 5,410,393 shares of the company were exchanged, compared to its average volume of 901,912. The company has a market capitalization of $14.20 billion, a PE ratio of -74.10 and a beta of 0.69. The business has a fifty day moving average of $171.24 and a 200 day moving average of $139.87. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos has a 1-year low of $80.90 and a 1-year high of $243.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s quarterly revenue was up 58.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.16) EPS. As a group, sell-side analysts expect that Glaukos will post -0.32 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Alex Thurman sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert Kliman sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares of the company’s stock, valued at $7,107,140. This trade represents a 6.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 83,025 shares of company stock valued at $14,950,006. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Glaukos

A number of institutional investors have recently modified their holdings of the company. Allworth Financial LP bought a new position in Glaukos in the second quarter worth $28,000. CoreCap Advisors LLC bought a new stake in shares of Glaukos during the 3rd quarter valued at about $33,000. Fortitude Family Office LLC purchased a new stake in Glaukos during the third quarter valued at approximately $36,000. IFP Advisors Inc increased its stake in shares of Glaukos by 523.4% in the 2nd quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 246 shares in the last quarter. Finally, Parallel Advisors LLC increased its holdings in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 226 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Third-quarter revenue rose 58% year over year to $211.0 million, substantially exceeding the roughly $168 million analyst estimate. Adjusted EPS of $0.47 also surpassed consensus expectations for a loss, while reported net income reached $2.0 million, or $0.03 per diluted share, compared with a loss a year earlier. Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
• Positive Sentiment: Glaukos raised its 2026 sales forecast to $775 million-$785 million from $680 million-$700 million and introduced a preliminary 2027 sales goal of $1 billion. The target suggests management expects continued rapid adoption across its glaucoma and corneal-health franchises. Glaukos Corporation Provides Sales Guidance for 2027
• Positive Sentiment: Analysts lifted their price targets following the earnings report: Needham raised its target to $251 and maintained a buy rating, while BTIG and Stifel raised targets to $234 and $225, respectively. Wells Fargo increased its target to $226 and assigned an overweight rating. Needham analyst rating
• Neutral Sentiment: The quarter generated $14.8 million in operating cash flow, and Glaukos ended it with $162.3 million in cash and cash equivalents. These figures provide financial flexibility, although the company remains loss-making on some profitability measures.
• Negative Sentiment: Profitability was less robust under GAAP than the adjusted EPS headline indicates: operating profit was only $0.8 million, and the company continues to report a negative net margin. In addition, the referenced insider-trading data shows 32 open-market sales and no purchases over the past six months, which may temper enthusiasm at the elevated valuation.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.